Results demonstrated that pro-inflammatory lymphocytes represented by CD8 T cells were significantly enriched in NSCLC patients with SETBP1 mutations (all P < 0.05; Supplementary Figure 7A, 7B). This evidence concerns the gene SETBP1 and non-small cell lung carcinoma.